Johnson & Johnson’s newly formed consumer business has been targeted by claims its talcum powder can cause cancer, Jamie Smyth and Nicholas Megaw of The Financial Times reports. Kenvue has been named in seven talc lawsuits since the start of April, the Times says, according to regulatory filings and people familiar with the matter. Kenvue starts its IPO roadshow this week and will sell over-the-counter medicine and healthcare brands. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on JNJ:
- Alkermes arbitration award better than expected, says Mizuho
- Legend Biotech price target raised to $90 from $79 at BMO Capital
- Alkermes receives second interim award in Janssen arbitration
- Johnson & Johnson management to meet virtually with Oppenheimer
- Arcellx price target raised to $58 from $45 at Guggenheim